Saturday 17 October 2026
Export MIRA’s income statement to Excel — free account
MIRA Pharmaceuticals, Inc.
MIRA Healthcare Drug Manufacturers General
In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 50.8%, each against the same quarter a year earlier.
0.63
0.03
−4.55%
Follow MIRA
MIRA Pharmaceuticals, Inc. (MIRA) P/E ratio
MIRA Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MDCX Medicus Pharma Ltd compare | n/m |
| SCLX Scilex Holding Company compare | n/m |
| AMRN Amarin Corporation PLC compare | n/m |
| MIRA MIRA Pharmaceuticals, Inc. | n/m |
| GRFS Grifols, S.A. compare | 8.5× |
| OGN Organon & Co. compare | 17.4× |
| SNY Sanofi compare | 21.3× |
| BIIB Biogen Inc. compare | 41.0× |
| NSRX Nasus Pharma Ltd. compare | — |
| Drug Manufacturers General industry median | 24.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)